Cynata Therapeutics Ltd (CYP) - Net Assets
Based on the latest financial reports, Cynata Therapeutics Ltd (CYP) has net assets worth AU$5.98 Million AUD (≈ $4.23 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.20 Million ≈ $5.09 Million USD) and total liabilities (AU$1.22 Million ≈ $860.53K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Cynata Therapeutics Ltd's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$5.98 Million |
| % of Total Assets | 83.1% |
| Annual Growth Rate | 3.17% |
| 5-Year Change | -78.92% |
| 10-Year Change | -30.31% |
| Growth Volatility | 121.32 |
Cynata Therapeutics Ltd - Net Assets Trend (2007–2025)
This chart illustrates how Cynata Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. See Cynata Therapeutics Ltd (CYP) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cynata Therapeutics Ltd (2007–2025)
The table below shows the annual net assets of Cynata Therapeutics Ltd from 2007 to 2025. For live valuation and market cap data, see Cynata Therapeutics Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$5.98 Million ≈ $4.23 Million |
-17.12% |
| 2024-06-30 | AU$7.22 Million ≈ $5.11 Million |
-56.87% |
| 2023-06-30 | AU$16.73 Million ≈ $11.84 Million |
-30.16% |
| 2022-06-30 | AU$23.96 Million ≈ $16.95 Million |
-15.55% |
| 2021-06-30 | AU$28.37 Million ≈ $20.08 Million |
+68.98% |
| 2020-06-30 | AU$16.79 Million ≈ $11.88 Million |
+53.04% |
| 2019-06-30 | AU$10.97 Million ≈ $7.76 Million |
-28.70% |
| 2018-06-30 | AU$15.39 Million ≈ $10.89 Million |
+10.98% |
| 2017-06-30 | AU$13.86 Million ≈ $9.81 Million |
+61.53% |
| 2016-06-30 | AU$8.58 Million ≈ $6.07 Million |
-1.91% |
| 2015-06-30 | AU$8.75 Million ≈ $6.19 Million |
-11.21% |
| 2014-06-30 | AU$9.85 Million ≈ $6.97 Million |
+499.85% |
| 2013-06-30 | AU$1.64 Million ≈ $1.16 Million |
+92.43% |
| 2012-06-30 | AU$853.75K ≈ $604.08K |
-12.16% |
| 2011-06-30 | AU$971.93K ≈ $687.70K |
+4.28% |
| 2010-06-30 | AU$932.00K ≈ $659.45K |
-3.12% |
| 2009-06-30 | AU$961.98K ≈ $680.66K |
-56.48% |
| 2008-06-30 | AU$2.21 Million ≈ $1.56 Million |
-35.17% |
| 2007-06-30 | AU$3.41 Million ≈ $2.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cynata Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8989377100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$89.52 Million | 1496.54% |
| Other Comprehensive Income | AU$8.17 Million | 136.61% |
| Total Equity | AU$5.98 Million | 100.00% |
Cynata Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Cynata Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SQX Resources Ltd
AU:SQX
|
$3.02 Million |
|
HiteJinro Holdings Co Ltd
KO:000145
|
$3.03 Million |
|
Secure Trust Bank PLC
LSE:STB
|
$3.03 Million |
|
TOMCO ENERGY POST CON.
F:NI41
|
$3.03 Million |
|
Petrotal Corp
LSE:PTAL
|
$3.02 Million |
|
Airtouch Solar Ltd
TA:ARTS
|
$3.02 Million |
|
Yimutian Inc. American Depositary Shares
NASDAQ:YMT
|
$3.02 Million |
|
Khandwala Securities Limited
NSE:KHANDSE
|
$3.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cynata Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,217,235 to 5,981,735, a change of -1,235,500 (-17.1%).
- Net loss of 9,390,586 reduced equity.
- Share repurchases of 522,264 reduced equity.
- New share issuances of 8,136,935 increased equity.
- Other comprehensive income increased equity by 260,475.
- Other factors increased equity by 279,940.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-9.39 Million | -156.99% |
| Share Repurchases | AU$522.26K | -8.73% |
| Share Issuances | AU$8.14 Million | +136.03% |
| Other Comprehensive Income | AU$260.48K | +4.35% |
| Other Changes | AU$279.94K | +4.68% |
| Total Change | AU$- | -17.12% |
Book Value vs Market Value Analysis
This analysis compares Cynata Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.62x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.02x to 0.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | AU$0.99 | AU$0.02 | x |
| 2008-06-30 | AU$0.65 | AU$0.02 | x |
| 2009-06-30 | AU$0.28 | AU$0.02 | x |
| 2010-06-30 | AU$0.24 | AU$0.02 | x |
| 2011-06-30 | AU$0.19 | AU$0.02 | x |
| 2012-06-30 | AU$0.09 | AU$0.02 | x |
| 2013-06-30 | AU$0.07 | AU$0.02 | x |
| 2014-06-30 | AU$0.22 | AU$0.02 | x |
| 2015-06-30 | AU$0.14 | AU$0.02 | x |
| 2016-06-30 | AU$0.12 | AU$0.02 | x |
| 2017-06-30 | AU$0.17 | AU$0.02 | x |
| 2018-06-30 | AU$0.17 | AU$0.02 | x |
| 2019-06-30 | AU$0.11 | AU$0.02 | x |
| 2020-06-30 | AU$0.16 | AU$0.02 | x |
| 2021-06-30 | AU$0.22 | AU$0.02 | x |
| 2022-06-30 | AU$0.17 | AU$0.02 | x |
| 2023-06-30 | AU$0.12 | AU$0.02 | x |
| 2024-06-30 | AU$0.04 | AU$0.02 | x |
| 2025-06-30 | AU$0.03 | AU$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cynata Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -498.14%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.20x
- Recent ROE (-156.99%) is below the historical average (-92.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -67.25% | -424.10% | 0.15x | 1.05x | AU$-1.71 Million |
| 2009 | -150.76% | 0.00% | 0.00x | 1.48x | AU$-1.55 Million |
| 2010 | -227.05% | -1858.22% | 0.09x | 1.34x | AU$-2.21 Million |
| 2011 | -263.91% | -1150.54% | 0.18x | 1.25x | AU$-2.66 Million |
| 2012 | -180.65% | -949.39% | 0.16x | 1.19x | AU$-1.63 Million |
| 2013 | -55.74% | -2696.09% | 0.02x | 1.09x | AU$-1.08 Million |
| 2014 | -30.85% | -12130.51% | 0.00x | 1.01x | AU$-4.03 Million |
| 2015 | -42.42% | -1299.82% | 0.03x | 1.04x | AU$-4.59 Million |
| 2016 | -57.55% | -449.16% | 0.12x | 1.05x | AU$-5.80 Million |
| 2017 | -32.84% | -260.37% | 0.12x | 1.03x | AU$-5.94 Million |
| 2018 | -29.68% | -332.05% | 0.09x | 1.05x | AU$-6.10 Million |
| 2019 | -77.22% | -647.44% | 0.11x | 1.12x | AU$-9.57 Million |
| 2020 | -21.67% | -51.90% | 0.40x | 1.04x | AU$-5.32 Million |
| 2021 | -27.10% | -497.38% | 0.05x | 1.06x | AU$-10.53 Million |
| 2022 | -22.73% | -70.08% | 0.29x | 1.11x | AU$-7.84 Million |
| 2023 | -85.32% | -863.05% | 0.09x | 1.14x | AU$-15.95 Million |
| 2024 | -135.02% | -420.82% | 0.28x | 1.16x | AU$-10.47 Million |
| 2025 | -156.99% | -498.14% | 0.26x | 1.20x | AU$-9.99 Million |
Industry Comparison
This section compares Cynata Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,565,895
- Average return on equity (ROE) among peers: -157.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cynata Therapeutics Ltd (CYP) | AU$5.98 Million | -67.25% | 0.20x | $3.02 Million |
| Adalta Ltd (1AD) | $7.49 Million | -79.00% | 0.24x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $1.80 Million | -379.70% | 1.37x | $14.31 Million |
| ACRUX Ltd (ACR) | $3.28 Million | -177.05% | 1.74x | $4.36 Million |
| Actinogen Medical Ltd (ACW) | $9.37 Million | -34.06% | 0.09x | $78.71 Million |
| Argenica Therapeutics Ltd (AGN) | $8.31 Million | -49.24% | 0.09x | $10.00 Million |
| Arovella Therapeutics Ltd (ALA) | $10.51 Million | -87.53% | 0.53x | $60.73 Million |
| Anatara Lifesciences Ltd (ANR) | $535.97K | -364.70% | 1.14x | $1.92 Million |
| Alterity Therapeutics Ltd (ATH) | $5.61 Million | -198.54% | 0.38x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $4.87 Million | -107.62% | 0.09x | $41.77 Million |
| Avecho Biotechnology Ltd (AVE) | $3.90 Million | -102.34% | 0.23x | $40.65 Million |
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more